• Chloroquine: A Mechanism-to-Assay Framework

  2026-09-02

  Chloroquine is more than an autophagy inhibitor: its lysosomal, endosomal, immune, and mitochondrial effects can reshape experimental readouts. This article presents a mechanism-to-assay framework and shows how ferroptosis research offers a disciplined model for interpreting chloroquine data.

• Pitavastatin (NK-104): In Vitro Workflow Guide

  2026-09-02

  Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibitor for controlled cholesterol-biosynthesis experiments in cellular and biochemical systems. This guide supports assay setup, solubility handling, and QC, but the available dossier does not establish a directly matched paper protocol or validate clinical, animal, or therapeutic use.

• ML385: Practical NRF2 Inhibition Workflows

  2026-09-01

  ML385 provides a selective way to interrogate NRF2-dependent antioxidant defenses, ferroptosis, and cancer therapeutic resistance rather than relying on nonspecific oxidative-stress changes. This guide translates product specifications and liver-injury findings into reproducible cell-based, combination-treatment, and pathway-validation workflows.

• Azilsartan (TAK-536) in RAS and Neuroinflammation

  2026-08-31

  Azilsartan (TAK-536) is a selective AT1 receptor inverse agonist with a supplier-reported IC50 of 2.6 nM. Its use as an AT1 perturbation tool connects renin–angiotensin system studies with reactive astrocyte and microglia inflammation models, while current evidence remains primarily mechanistic and cell-based.

• Dextrose (D-glucose) for Hypoxia Assays

  2026-08-31

  Build reproducible glucose-availability experiments with Dextrose (D-glucose), from defined cell culture supplementation to hypoxia–immunometabolism studies. The workflow emphasizes concentration matrices, matched oxygen conditions, fresh solution handling, and controls that separate cellular energy production from osmotic or handling artifacts.

• Thymoquinone Protects Against Doxorubicin Cardiotoxicity

  2026-08-30

  A 2025 mouse study identifies Thymoquinone as a potential modulator of doxorubicin-induced cardiac injury, linking functional protection with Nrf2/HO-1 activation, redox improvement, ferroptosis-related proteins, and preserved mitochondrial structure. The work provides a mechanistic preclinical framework for testing redox-directed interventions in chemotherapy-associated cardiotoxicity, while leaving dose translation and effects on antitumor efficacy unresolved.

• PD98059: From MAPK Mechanism to Translation

  2026-08-29

  PD98059 is more than a pathway inhibitor: it is a practical probe for testing whether MEK–ERK signaling connects environmental exposure to vascular lipid dysregulation. This thought-leadership article examines evidence from a recent nanoplastic study, defines rigorous validation strategies, and positions PD98059 within translational cancer, vascular, and neuroprotection research.

• Naftifine HCl: Mechanism-to-Assay Strategy

  2026-08-29

  Naftifine HCl is an allylamine antifungal agent for studying fungal sterol disruption through squalene 2,3-epoxidase inhibition. This article develops a mechanism-first assay framework and uses the WNT5a/GSK3/β-catenin study as a disciplined example of how pharmacological perturbations should be interpreted across biological systems.

• JNJ-10198409: PDGF Receptor Inhibitor Workflows

  2026-08-28

  JNJ-10198409 supports dose-resolved studies of PDGF-BB receptor signaling in smooth muscle, angiogenesis, tumor, and fibrotic models. Its ATP-competitive mechanism is especially useful when paired with time-course phospho-signaling, proliferation, migration, and viability readouts rather than a single endpoint.

• Mithramycin A in Mechanistic Assays

  2026-08-28

  Mithramycin A is an anticancer antibiotic that converts G-C-rich DNA binding into a practical probe for transcriptional regulation, c-myc biology, and differentiation studies. This guide connects its established cancer research uses with a carefully bounded assay extension inspired by the miR-24-3p/Sp1/PI3K heart-failure study.

• Recombinant Mouse SHH in Developmental Translation

  2026-08-27

  A mechanistic and strategic guide to using Recombinant Mouse Sonic Hedgehog as a controlled perturbation tool in developmental biology, comparative embryology, and congenital malformation research.

• Wnt Agonist 1: From Pathway Control to Translation

  2026-08-27

  Wnt agonist 1 (BML-284) offers a practical chemical lever for testing how canonical Wnt signaling reshapes cell state, differentiation, and therapy response. This thought-leadership analysis connects pathway activation to the Wnt/NR2F2/GPX4 axis reported in lung cancer brain metastasis while defining the controls needed for translationally credible experiments.

• AM 281 for CB1 Receptor Research

  2026-08-26

  AM 281 enables selective interrogation of CB1 signaling across receptor, astrocyte, neuronal survival, and cognition assays. This workflow-focused guide connects compound handling with the CB1–CREB–GLT-1 mechanism reported in traumatic brain injury and highlights controls for memory impairment research and addiction-related studies.

• GDC-0994: Practical ERK1/2 Inhibitor Workflows

  2026-08-26

  GDC-0994 enables controlled ERK1/2 inhibition across oncogenic signaling assays and estrogen-associated cholestasis models. This guide connects target engagement, pathway readouts, rescue experiments, and troubleshooting into practical workflows for reproducible research.

• AMPK, ULK1, and the Energy-Stress Response

  2026-08-25

  Park, Lee, and Kim challenge the prevailing view that AMPK universally stimulates autophagy during glucose deprivation. Their study shows that AMPK restrains ULK1-dependent autophagy initiation during acute energy stress while preserving the autophagy machinery for recovery after stress subsides.

453 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page